GEOVANNA DEESE: Open Payments
NPI 1558534768 · CHARLOTTE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,282 in 343 payments from 25 companies in 2025. Trend: 2023 $4,813 · 2024 $6,072 · 2025 $7,282
Food & beverage: $7,198Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 94 | $1,885 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 43 | $673 |
| Madrigal Pharmaceuticals | 20 | $554 |
| Janssen Biotech, Inc. | 19 | $535 |
| Aimmune Therapeutics, Inc. | 19 | $514 |
| QOL Medical, LLC | 19 | $438 |
| VIVUS LLC | 19 | $389 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $366 |
| Phathom Pharmaceuticals, Inc. | 15 | $358 |
| Lilly USA, LLC | 14 | $349 |
Products named: SKYRIZI, RINVOQ, REZDIFFRA, XIFAXAN, TREMFYA, ZENPEP, Sucraid, PANCREAZE.
Industry payments across NC — which companies pay providers there.
